Matrix Pharmaceutical (MATX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matrix Pharmaceutical (MATX)

MATX 132.00

+0.7%

Jan 9 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike Keys who wrote (233)	10/27/1999 11:05:00 PM
From: JLIHAI	Read Replies (2) of 240

I don't have any details, but so far the clinical trials of Intradose have been going well. As part of the earnings release the CEO said he was looking forward to presenting results at the Nov 3 symposium. Since it's in New York instead of Europe, it seems to be attracting more attention to MATX. MATX already has fast-track approval status on the head and neck version. I'm wondering if they could get granted a separate similar status on the liver version. JL

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next